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Gamma secretase inhibitors (GSIs) comprise a growing class of
compounds that interfere with the membrane-bound Notch
signaling protein and its downstream intra-nuclear transcrip-
tional targets. As GSI-I (Z-LLNle-CHO) is also a derivative of a
widely used proteosome inhibitor MG-132, we hypothesized
that this compound might be active in precursor-B acute
lymphoblastic leukemia (ALL) cell lines and patient samples.
We found that GSI-I treatment of precursor-B ALL blasts
induced apoptotic cell death within 18–24h. With conﬁrmation
using RNA and protein analyses, GSI-I blocked nuclear
accumulation of cleaved Notch1 and Notch2, and inhibited
Notch targets Hey2 and Myc. Microarray analyses of 207
children with high-risk precursor-B ALL demonstrate that Notch
pathway expression is a common feature of these neoplasms.
However, microarray studies also implicated additional tran-
scriptional targets in GSI-I-dependent cell death, including
genes in the unfolded protein response, nuclear factor-jB and
p53 pathways. Z-LLNle-CHO blocks both c-secretase and
proteosome activity, inducing more robust cell death in
precursor-B ALL cells than either proteosome-selective or
c-secretase-selective inhibitors alone. Using Z-LLNle-CHO in a
nonobese diabetes/severe combined immunodeﬁciency (NOD/
SCID) precursor-B ALL xenograft model, we found that GSI-I
alone delayed or prevented engraftment of B-lymphoblasts in
50% of the animals comprising the experimental group,
suggesting that this compound is worthy of additional testing.
Leukemia (2011) 25, 1135–1146; doi:10.1038/leu.2011.50;
published online 15 April 2011
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Introduction
Precursor-B acute lymphoblastic leukemia (precursor-B ALL) is
the most common neoplasm in children and young adults.
Although most patients appear to be cured, survivors commonly
develop morbidities that result from dose-intensiﬁed treatment
with cytotoxic drugs. And, despite the use of aggressive salvage
treatments, those who relapse have a dismal prognosis, under-
scoring the need for improved treatment options. Among a
number of novel therapeutic options, g-secretase and proteo-
some inhibitors have recently shown biologic activity in
T-lineage ALL (T-ALL),
1 but remain to be fully deﬁned for
precursor-B ALL.
2 When administered in animal models, GSIs
have a range of biological activities, including an ability to
reduce the accumulation of amyloid peptides associated with
Alzheimer’s disease, and can induce apoptosis in a variety of
tumors, included breast cancer cells.
3 In this report, we focus on
gamma secretase inhibitor-I (GSI-I; Z-LLNle-CHO), which is
structurally similar to the widely used proteosome inhibitor
MG-132, and describe its biological activity in precursor-B ALL.
Recent studies in multiple myeloma and in lymphoma-
derived B-cell lines suggest that GSI sensitivity may be a general
property of mature B-cell neoplasms.
4–6 Herein, we establish
that GSI-I induces apoptosis in cultured precursor-B ALL cell
lines and freshly isolated blasts. GSI-I also showed antitumor
activity in a xenograft of human precursor-B ALL established in
immuno-deﬁcient nonobese diabetes/severe combined immu-
nodeﬁciency (NOD/SCID) mice. We conﬁrm that Notch
receptors are at least one important downstream target impacted
by GSI-I, consistent with their established role as g-secretase
substrates that control multiple aspects of lymphoid develop-
ment and function. This work raises important questions
regarding the complexity of Notch signaling in early B-cell
development,
7 because precursor-B blast cells are shown to
express three of the four Notch receptors (Notch 1–4) and ﬁve
ligands (Delta-like-1, Delta-like-3, Delta-like-4, Jagged-1 and
Jagged-2) (see ref. 8 for a review of these proteins). We evaluate
speciﬁc Notch target genes, including members of the HES, HEY
and Myc.
8–12 We conﬁrm the observations of Han et al.
3 that
GSI-I is also a potent proteosome inhibitor, broadening the
range of targets in leukemia blasts. We show that GSI-I treatment
disrupts Akt-dependent pro-survival pathways
13 and elevates
reactive oxygen species (ROS) levels,
14 consistent with previous
reports that g-secretase and proteosome targets regulate
apoptotic cell death pathways.
14,15 We extend these observa-
tions to show that GSI-I has biological activity in precursor-B
ALL cells and may be a suitable candidate for further testing in
phase 1 clinical trials.
Materials and methods
Cell lines and institutional patients
B-linage cell lines (Nalm-6, 697, MHH-Call3, RS4;11; Tanoue)
were from DSMZ-Deutsche Sammlung von Mikroorganismen
Received 24 March 2009; revised 7 January 2011; accepted
17 February 2011; published online 15 April 2011
Correspondence: Dr SS Winter, T John Gribble Endowed Chair,
Pediatric Hematology/Oncology, MSC 10 5590, 1 University of New
Mexico, Albuquerque, NM 87131, USA.
E-mail: swinter@salud.unm.edu
8Current address: Department of Obstetrics and Gynecology,
University of Iowa, Iowa City, IA 52242, USA.
9Ergen Family Chair in Pediatric Cancer.
10These authors contributed equally to this work.
Leukemia (2011) 25, 1135–1146
& 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11
www.nature.com/leuund Zellkulturen GmbH (Braunschweig, Germany). Cells were
cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA)
with 10% fetal bovine serum. Bone marrow samples were
acquired at diagnosis from pediatric patients with written,
informed consent per local institutional human research guide-
lines. Mononuclear cells were enriched by Ficoll–Paque
centrifugation; for DNA/RNA preparation, B-lineage cells were
isolated at 41C using anti-CD19 magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). Patients received risk-
adjusted therapy according to protocols sponsored by the
Children’s Oncology Group. Peripheral blood B cells were
isolated from the buffy coats of normal blood donors (United
Blood Services, Albuquerque, NM, USA).
Reagents and antibodies
GSI-I (Z-LLNle-CHO), L-685,458, GSI-IX (DAPT) and GSI-XII
(X-IL-CHO) were from Calbiochem (San Diego, CA, USA).
Compound E was from Axxora LLC (San Diego, CA, USA). Cell
Signaling Technology (Danvers, MA, USA) was the source of the
PathScan Multiplex western cocktail I, the Phospho-Akt Path-
way Sampler Kit, and antibodies to caspase 9 (Asp330), caspase
3 (8G10), Notch1 (6A5) and phospho-FoxO1/FoxO3. Notch 2
antibodies (ab8927) were from Abcam (Cambridge, MA, USA);
Notch 3 (active) antibodies were from Epitomics (Burlingame,
CA, USA).
Western blotting
Cells (5–10 10
6) were lysed in ice-cold buffer (50mM Tris-HCl
pH 7.2, 150mM NaCl, 1mM NaVO3, protease inhibitor cocktail
from Boehringer-Mannheim (Indianapolis, IN, USA), 1%
NP-40). Lysates were clariﬁed by centrifugation (15000g for
5min) and protein levels measured by the Pierce bovine serum
albumin method to normalize loading for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Where indicated,
nuclear/cytosol fractions were prepared (NE-PER reagents,
Pierce, Rockford, IL, USA). Blocked membranes were sequen-
tially incubated with 11 antibodies and horseradish peroxidase-
conjugated 21 antibodies (Jackson, West Grove, PA, USA) and
imaged using the chemiluminescence protocol.
Apoptosis and ROS production
Cell viability was assessed by Trypan blue exclusion and WST-1
assay (Roche Diagnostics Corporation, Indianapolis, IN, USA).
To measure apoptosis, cells were labeled with annexin V-PE
detection kit I (Pharmingen, San Diego, CA, USA) and data
acquired on a FACS Calibur (Becton Dickinson, Franklin Lakes,
NJ, USA) Screening for 35 apoptosis-related proteins was
accomplished using the human apoptosis array from R&D
Systems (Minneapolis, MN, USA). ROS production was mea-
sured by ﬂow cytometry, after loading cells with 5-(and 6-)
chloromethyl-20,70-dichlorodihydroﬂuorescein diacetate, acetyl
ester (CM-H2DCFDA; Invitrogen), a dye that increases ﬂuores-
cence with oxidation.
PCR analysis
Qiagen RNAeasy Mini and OneStep RT-PCR kits (Qiagen,
Valencia, CA, USA) were used for RNA isolation and reverse
transcriptase-polymerase chain reactions (RT-PCR). Primer sets
were designed such that ampliﬁcations crossed intron–exon
boundaries to exclude genomic DNA. Quantitative RT-PCR
used the QuantiTect Reverse Transcription and SYBR Green
PCR kits, with speciﬁc primer sets.
Microarray analyses
RNA from 697 precursor-B ALL cell line and cryo-preserved
bone marrow or peripheral blood patient samples was extracted
using Trizol (Invitrogen) followed by ampliﬁcation, and hybri-
dization to Affymetrix HG-U133Plus2.0 oligonucleotide micro-
arrays (https://www.affymetrix.com). The gene expression data
set was derived from a cohort of high-risk B precursor ALL
patients enrolled on COG ALL biology and treatment trials 9900
and 9906, respectively. Analysis of patient samples was
performed using Affymetrix GCOS (GeneChip Operating Soft-
ware) v1.4 (Affymetrix, Santa Clara, CA, USA). The Microarray
Suite 5.0 statistical algorithm was applied and signal intensities
and present/marginal/absent calls obtained. Control data were
obtained from bone marrow CD19þ cells of six healthy
subjects, analyzed as a separate cohort. The entire gene
expression data set may be accessed via the National Cancer
Institute caArray portal (https://array.nci.nih.gov/caarray) or at
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo; accession no. GSE11877).
Microarray data of drug-treated 697 cell line samples were
subjected to quantile normalization using the PLIER-sketch
algorithm in Affymetrix Power Tools 1.8, with the pm-mm
background correction ﬂag turned on. Normalized data were
analyzed using R (https://www.r-project.org) and Bioconductor.
Brieﬂy, data were ﬁltered to ﬁnd expressed genes by requiring
that at least two samples gave a signal greater than 256
normalized Affymetrix units. The LIMMA
16 package was used to
identify 383 probesets that were signiﬁcantly (P-value 0.02)
changed at least threefold between the two experimental
conditions, using a Benjamini–Hochberg false discovery rate
correction. Independently, a set of 342 probesets was identiﬁed
using the SAMR algorithrm
17 and a two class paired signiﬁcance
test with a delta of 4.0. The ﬁnal list of genes with signiﬁcant
changes in expression was based on intersection of these
two lists.
Murine xenograft model
Female SCID/NOD mice (6–8-week-old; pathogen free; Harlan
Sprague Dawley Inc., Indianapolis, IN, USA) were purchased
and housed in a speciﬁc pathogen free, AAALAC accredited
facility in autoclaved static microisolation caging and paper
bedding with ad libitum irradiated rodent diet (Harlan Teklad
Tek-Fresh Bedding and 2918 Teklad Global rodent diet,
Madison WI, USA) and acidiﬁed ﬁltered drinking water
(HydroPac water pouches, Lab Products Inc., Seaford, DE,
USA). In addition to pathogen-free vendor health reports, the
animal resource facility conducts periodic quality assurance
health testing and assures that these mouse populations have
remained free of pathogenic and opportunistic infectious agents.
The macroenvironmental conditions within the room were
maintained at 20–24.41C (68–761F) and 28–35% relative
humidity, 10–15 air changes hourly and 12:12h light:dark
cycle. All procedures with animals complied with our Public
Health Services Policy on humane care and use of laboratory
animals and according to the animal protocol approved by the
Institutional Animal Care and Use Committee. Within a set of 24
SCID/NOD mice, one was used to harvest control normal
histologies, 11 were assigned to the control group (precursor-B
ALL without GSI-I) and 12 animals were assigned to the
treatment group (precursor-B ALL with GSI-I). After 28 days,
mice were subcutaneously injected with phosphate-buffered
saline-vehicle or GSI-I (5mg/kg) in 250ml of normal saline daily
over a 12-day period (5 days on, 2 days off, 5 days on). Surviving
mice were killed on day 72 after engraftment. In cases where the
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showed signs of decreased movement, following euthanasia,
necropsies were performed using standard IACUC-approved
techniques.
Histology and immunohistochemistry
Blood and bone marrow samples from control or engrafted mice
were slide mounted and Wright stained. For each sample, percent
blasts were scored in triplicate for groups of 100 peripheral
mononuclear blood cells. Liver, spleen and bone marrow
sections were ﬁxed in 10% neutral-buffered formalin (Sigma-
Aldrich, St Louis, MO, USA), dehydrated and embedded in
parafﬁn, sectioned and stained with hematoxylin and eosin. For
immunohistochemistry, bone marrow sections were rehydrated
through a xylene followed by the graded alcohol series.
Endogenous peroxidase activity was blocked with 3% hydrogen
peroxide and antigen retrieval was performed by pressurized
heating in a decloaking chamber (Biocare Medical, Concord, CA,
USA) in 0.01M citrate buffer (pH 6.0). Slide-mounted samples
were blocked in phosphate-buffered saline containing 5% goat
serum/0.5% Tween 20 for 30min then sequentially incubated
with rabbit anti-CD10 antibodies (Abcam, 1:50) at 41C and goat
anti-rabbit immunoglobulin G–horseradish peroxidase secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1:500) with washes between steps. Slides were stained with 303-
diaminobenzidine (BD Pharmingen, Sparks, MD, USA), counter-
stained with hematoxylin (Sigma-Aldrich) and dehydrated before
coverslips were mounted. Analysis was performed using a Zeiss
Axioscope upright microscope (Thornwood, NY, USA) equipped
with a digital camera.
Results
GSI-I induces death in cultured precursor-B ALL cells
and freshly isolated lymphoblasts
Mutations in the Notch signaling complex have been identiﬁed
in approximately 50% of patients with T-ALL, leading to the
understanding that Notch1 activation may be an important
aspect of T-ALL leukemogenesis.
18 As GSIs are important
inhibitors of Notch, select lead candidates are being investigated
in T-ALL phase 1 clinical trials.
1 Equally important, Notch
signaling has been shown to modulate early B-cell develop-
mental events,
4–6 leading us to hypothesize that GSIs may also
have biological importance in precursor-B ALL. To evaluate the
biological activity of GSI compounds in precursor-B ALL blasts,
we tested a panel of GSI compounds including GSI-I (Z-LLNle-
CHO), GSI-IX (DAPT), GSI-XII (X-IL-CHO) and compound E for
their biological activity in the 697 precursor-B cell line. Among
the compounds tested, GSI-I and the proteosome inhibitor
MG132 caused a 480% reduction in cell viability (Figure 1a),
while GSI-IX (DAPT), GSI-XII and compound E had no
signiﬁcant effects. On the basis of these results, we selected
GSI-I as our lead candidate for further testing in four precursor-B
ALL cell lines (Nalm6, 697, MHH-Call3 and RS4:11), which
represent important precursor-B ALL cytogenetic and phenoty-
pic subclasses (Supplementary Table 1). For comparison, we
included the B-ALL Tanoue B-cell line, which is derived from a
Burkitt’s lymphoma and expresses mature BCR. Data in
Figure 1b compare the dose response for GSI-I treatment of
these cell lines, as measured by WST-1 cell viability assay.
Nalm6, 697 and MHH-Call3 cells had similar responses, with
B50% cell death after 24 h treatment with 1.25mM GSI-I and
490% cell death for 2.5mM GSI-I. The RS4;11 pre-B-cell line
was very sensitive to the drug, with cell death occurring at only
0.5mM GSI-I. In contrast, 2.5mM GSI-I caused only about 20%
cell death in the more mature Tanoue cell line. The next set of
experiments (Figure 1c) show that GSI-I (2.5mM, 18h) induced
cell death in CD19þ precursor-B ALL blasts isolated from eight
patients, including two relapse cases (#0596R and #2707R). In
contrast, peripheral blood B cells, isolated from the buffy coat of
a healthy control were 490% viable after the 18-h treatment
period.
As the precursor-B ALL cell lines showed a response to the
MG132 proteosome inhibitor, we next tested whether the same
panel of GSIs had comparable effects to proteosomal inhibitorial
effects of bortezomib. In Figure 1d, we compare the relative
inhibition of proteosome activity for bortezomib and MG132
(two known proteosome inhibitors) with four g-secretase
inhibitors. GSI-I essentially abolished proteosome activity while
GSI-XII showed B50% inhibition. Neither GSI-IX nor com-
pound E had signiﬁcant effects on proteosome activity. Results
in Figure 1e show that blasts from individual patients can be
relatively resistant to the proteosome inhibitor, bortezomib. Of
the four samples tested, blasts from patient 3018 remained
100% viable after 24-h incubation with 1–10mM bortezomib.
This contrasts with only 10% viability for blasts from this patient
after 24-h incubation with GSI-I (Figure 1c). Blasts from three
other patients showed only 40–60% loss of viability at the
highest bortezomib concentration. Together, these data
suggested to us that the effectiveness of GSI-I might be explained
by disruption of other pathways that synergize with Notch
pathway inhibition to induce cell death. These results also allowed
us to conclude that GSI-I has biological activity in precursor-B ALL
cell lines and, equally important, in a diverse array of patient
samples having intermediate and high-risk characteristics.
Evidence that GSI-I causes cell death through both
Notch-dependent and Notch-independent pathways
To address our hypothesis that GSI-I induces cell death in
pathways that interact synergistically with Notch, we evaluated
global gene expression changes in GSI-I-treated 697 precursor-B
ALL cells (6h) using Affymetrix microarrays. Results were
dramatic, with 42-fold changes in expression of over 1300
genes within 6h of GSI-I treatment. Figures 2a–d illustrate
results for three classes of transcriptional targets that stood out in
the data set. First, we noted that many of the genes upregulated
after GSI-I treatment were signatures of stress response. The most
remarkable examples are mRNA transcripts encoding HSP70
family members: HSPA6 and HSPA1A, whose expression
increased 500- and 75-fold, respectively (Figure 2a). Levels of
DNAJB1 mRNA, which encodes an HSP40 protein, also rose at
12–14-fold. In addition, there are transcriptional changes typical
for unfolded protein response. GSI-I treatment of precursor-B
ALL cells induced remarkable upregulation of CHAC1 (up
56-fold) and ATF3 (up 15-fold), two genes whose expression
was recently associated with chemically induced unfolded
protein stress response.
19 For probeset IDs, see Supplementary
Tables 3A and B. Importantly, western blots in Figure 2b conﬁrm
protein signatures consistent with stress response (elevated
levels of HSP70 as well as phosphorylated forms of JNK and
ATF2).
A second important category of transcriptional alterations
were signatures of p53 induction (Figure 2c), including marked
upregulation of SESN2 and UNC5B expression. GSI-treatment
induced smaller, but signiﬁcant, induction of p53 target
genes NOXA, GADD45 and CDKN1A. Consistent with these
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phosphorylation after GSI-I treatment.
The third important category reﬂects changes in known Notch
target genes, an expected outcome of GSI-I treatment. Figure 2d
reports these data, as measured by microarray methods and
conﬁrmed by quantitative PCR. Expression of Hey2, Myc and
Deltex were reduced 2–4-fold after 6h of GSI-I treatment. In
contrast, expression of Hes1 and Hey1 increased by 4–20-fold
in cells treated with GSI-I.
Expression proﬁling demonstrate GSI-I-induced
transcriptional changes in B cells
In addition to the three main categories detailed in Figures 2a–d,
the heatmap representation in Figure 2e illustrates the top 190
genes displaying the most dramatic and consistent changes in
the precursor-B ALL transcription after GSI-I treatment. Genes of
particular interest with respect to B-cell function or development
are indicated to the right of the heatmap. A more extensive
listing of gene expression differences after GSI-I treatment is
found in Supplementary Tables 3A, B. Notable downregulated
genes include CD79B, which encodes the immunoglobulin-b
subunit common to both the mature and pre-BCR. There was an
85% drop in levels of CXXC5, implicated in nuclear factor
(NF)kB activation.
20 In contrast, there was a 12-fold induction of
ID2, whose overexpression is associated with a block of B-cell
development at the pre–pro B-cell state and with inhibition of
the B-cell commitment factor, E2A.
21 These results show that
multiple pathways are affected by GSI-I, including signaling
pathways that regulate NFkB activity and B-cell differentiation.
GSI-I treatment blocks Akt-mediated pro-survival
pathways and induces caspase- and ROS-dependent
cell death
Cell death in GSI-treated cells exhibits typical hallmarks of
apoptosis, including increases in annexin V-PE and 7-AAD
staining, as well as fragmentation of nuclei (Supplementary
Figure 1). To evaluate the mechanisms leading to apoptosis, we
next evaluated the effect of GSI-I on potential regulators of
Figure 1 GSI-I treatment induces apoptosis in pre-B-cell lines and primary patient blasts. (a) Precursor-B ALL cell viability for 697 cells was
abolished after 18h treatment with GSI-I (Z-LLNle-CHO), reduced by 80% after treatment with MG132 and unaffected by treatment with three
other GSI compounds. (b) GSI-1 induces cell death in precursor-B ALL cell lines with different cytogenetic characteristics. Tanoue B cells were
relatively resistant to GSI-I. (c) Overnight treatment of blast cells from children and young adult patients led to 50–99% loss in cell viability,
compared with only 10% loss of viability for normal peripheral blood B cells. (d) GSI-I inhibits proteosome activity at levels comparable to MG132
and bortezomib. (e) Bortezomib-induced cell death in patient samples is comparably less than that induced by GSI-I, as demonstrated in (d).
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proteolytic cleavage of their proenzyme forms. GSI-I caused a
reduction in full-length caspase 3 in Nalm6 and 697 cells
(Figure 3a), with a complementary increase in cleaved PARP, a
caspase 3 substrate. As shown in Figure 3a, caspase 3 cleavage
began as early as 6h into GSI-I treatment and was mostly
complete by 18h, and the cleaved form of caspase 9 was also
detected in GSI-treated 697 cells. GSI-I treatment also resulted
in the accumulation of ROS, as demonstrated in 697 cells
loaded with the dye, CM-H2DCFDA (Figure 3b). These results
suggest that GSI-I-mediated cell death in precursor-B ALL is
importantly dependent on both caspase activation and ROS
production. Supporting this, data in Figure 3c show that the
general caspase inhibitor Z-VAD signiﬁcantly prevented cell
death in 697 precursor-B ALL cells treated with GSI-I. The
oxidative scavenger, NAC, completely protected the viability of
GSI-I-treated 697 cells, indicating a critical role for ROS in this
process. By comparison, NAC failed to protect 697 cells from
cell death induced by bortezomib (data not shown).
Results in Figure 3d show that GSI-I treatment led to a drop in
total AKT protein levels, with no detectable phospho-AKT in 697
and 470% drop in phospho-Akt in Nalm6 cells (top). GSI-I
treatment of both 697 and Nalm6 cells also led to detection of
the BH3 domain-only protein, Bim. We hypothesized that the
loss of Akt and the production of Bim might be linked, through
regulation of the transcription factor FoxO3a (Forkheadbox,
class O) that contains multiple Akt consensus sequences
(RXRSSS/T).
22 FoxO3 phosphorylation prevents nuclear trans-
port of FoxO3a where it targets the FHER (FoxO-binding site) in
the Bim promoter.
23 We utilized phospho-speciﬁc FoxO3a
antibodies to probe membranes bearing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis separated proteins from
untreated and GSI-I-treated cells. Levels of total FoxO3 were
unperturbed by GSI-I treatment, but FoxO3 serine/threonine
phosphorylation was essentially ablated. Increase in FoxO3
transcriptional activity, associated with its dephosphorylation
after GSI-I treatment, was conﬁrmed by a DNA-pull down assay
(Supplementary Figure 2).
Notch receptors, ligands and target genes are all
expressed in freshly isolated pre-B lymphoblasts
Notch signaling events upregulate the expression of several
downstream targets, including HES1, HEY2 and MYC. On the
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Figure 2 Changes in levels of gene transcripts and proteins after GSI-I treatment in 697 cells. Graphs show relative changes in gene expression for
heat-shock proteins (a), p53 target genes (c) or Notch targets (d) after GSI treatment. Western blots in (b) show compare levels of heat shock
proteins and show increases in phoshorylation of JNK and ATF2. (e) Heatmap of signal intensity (in Affymetrix units) for probesets that were more
than threefold increased or decreased after 6 h treatment of 697 cells with 2.5mM GSI-I. Select genes are listed on the right and labeled either in red
(increased) or green (decreased). Data are representative of two independent experiments.
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4–6 Notch receptors and ligands
appear to be important targets of g-secretase activity in cells of
B-cell derivation. To evaluate Notch gene expression in our
precursor-B ALL cell lines and patient samples, we isolated RNA
from the Nalm6, 697 and Tanoue cell lines, as well as from
CD19þ cells recovered from the bone marrow of pediatric
precursor-B ALL patients. RT-PCR analysis showed that all cell
lines had strong signals for Notch1, Notch2 and Notch3, but not
for Notch4 (Figure 4a). All cell lines also had strong expression
Notch targets JAG1, JAG2, DLL1, DLL3 and DLL4. Similar
results in the GSI-I sensitive pre-B ALL cell lines, MHH-Call3
and RS4;11 (not shown). We note that the more mature Tanoue
B-cell line has similar proﬁle of Notch receptors and ligands, but
is resistant to GSI-I treatment (Figure 1b). This is consistent with
the concept that Notch-independent targets of GSI-I are
important contributors to GSI-I toxicity. We next extended our
observations for Notch signaling into a cohort of patients with
precursor-B ALL. This group of 11 patients harbored a range of
cytogenetic abnormalities (Supplementary Table 2). RT-PCR
analysis showed that all the patients had strong signals for
Notch1, Notch2 and Notch3; with one exception (patient #476),
all also expressed all ﬁve Notch ligands. Representative results
are shown in Figure 4b. To rule out a role for activating
mutations in Notch1, the heterodimerization and PEST domains
were ampliﬁed by RT-PCR and sequenced; no mutations were
found. Representative results for Hes1 expression in this patient
group are also shown in Figure 4a; again only patient #476 had
barely detectable message. In contrast to the ﬁndings shown for
precursor-B ALL cell lines and patient blasts, Notch signaling is
weak in mature, non-malignant donor B cells (Figure 4c). For all
experiments, RNA quality was conﬁrmed by RT-PCR analysis for
the housekeeping gene, GAPDH. These data show that Notch
signaling constitutively occurs in precursor-B ALL lines and most
pediatric B-ALL primary patient samples.
Protein levels of ligands and cleaved Notch receptors
Western blotting was used to conﬁrm the presence of Notch
ligand and receptor expression in precursor-B ALL cells.
Figure 4d documents presence of Jagged 1 and DLL4 protein
expression in precursor-B ALL cell lines. This ﬁgure also
illustrates detection of the cleaved intracellular Notch (ICN)
forms of Notch 1 and Notch 2 in nuclear fractions prepared from
the 697 cell line. Two bands were detected for ICN2, potentially
Figure 3 Induction of proapoptotic pathways after GSI-I treatment. (a) Top: GSI-I treatment leads to PARP and caspase 3 cleavage/activation in
Nalm6 and 697 cells but not Tanoue cells. Bottom: time course of caspase 9 and caspase 3 activation in GSI-I-treated 697 cells. (b) Time course of
ROS production in 697 cells after addition of 2.5mM GSI-I. (c) Protection of GSI-induced apoptosis in 697 cells by the caspase inhibitor, Z-VAD or
the ROS scavenger, N-acetylcysteine (NAC). (d) Western blotting results show GSI-induced changes in the total AKT, phospho-AKT, phospho-
FoxO3a and level of BimEL in lysates from 697, Nalm6 and Tanoue cells.
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Leukemiarepresenting different posttranslational modiﬁcations. In con-
trast, the cleaved form of Notch 3 (MW 97kD) was detected
only in the cytosol fraction. HSP90 and the nuclear factor, SP1,
served as markers for cytosol and nuclear fractions. Importantly,
GSI-I treatment led to a loss of both cleaved Notch 1 (ICN1) and
cleaved Notch 2 (ICN2) in the nuclear fractions of 697 cells. We
note that these results were obtained using pan-reactive
antibodies to Notch 1, not the commonly used NCT-Val
1744mAb that is speciﬁc to ICN1.
24 The reasons for our
inability to detect ICN1 using this reagent is unknown; possible
explanations include poor sensitivity because of low levels
(ICN1 is rapidly degraded
24), or differential proteolysis by the
presenilin-1 form of g-secretase. GSI-I failed to reduce levels of
activated Notch3 in pre-B cells. Together with the lack of
Notch3 ICN in the nucleus, we assume that Notch3 has
negligible roles in the events that follow GSI-I treatment.
Genomic analysis of Notch-related genes in a high-risk
pediatric cohort
Gene proﬁling provides a platform to screen a large number of
patients for alterations in RNA expression levels. We chose to
extend our observations regarding Notch signaling in precursor-
B ALL cells for three reasons. First, our ﬁndings in 11 patients
may have been unique to a limited subset of patients, and not
representative of a larger sample size. Second, while Notch-
activating mutations have been well described in patients with
T-ALL, the link between Notch signaling and precursor-B
development is poorly understood. Third, we wished to
investigate whether Notch expression patterns are restricted to
speciﬁc, genetically deﬁned patient subsets. Table 1 reports
analysis of an extensive Affymetrix data set recently completed
for 207 children and young adults enrolled on COG 9906 for
high-risk precursor-B ALL. CD19þ cells from healthy bone
marrow donors served as a normal control. Expression patterns
of 45 genes are reported here, representing all Notch receptor
and ligands as well as proteins critical to Notch processing,
signaling and regulation. Gray shading in the table highlights
genes where at least one probe set had signal intensity above a
threshold value of 225 normalized Affymetrix units. The table
reports the median signal for all patient samples across the gene
probe set, as well as the number of patients with values above
the threshold for expression of the gene. Approximately 97% of
the high-risk precursor-B ALL patients expressed signiﬁcant
Figure 4 Leukemic pre-B cells express Notch receptors, ligands and target genes. RT-PCR results for Notch receptors, ligands and target genes in
blasts from (a) three precursor-B ALL patients and normal peripheral blood B cells, (b) B lineage cell lines or (c) normal peripheral blood B cells.
(d) Western blots results at left detect JAG1 and DLL4 in 697 cell lysates. Results at right report relative distribution of Notch1, Notch2 and Notch3
ICNs between cytoplasmic and nuclear fractions prepared from 697 cells, ±GSI treatment. SP1 and Hsp90 serve as controls for nuclear and
cytosol fractions. Note that a truncated form of SP1 is found in the nucleus of GSI-I-treated cells, consistent with induction of apoptosis.
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Leukemiaamounts of NOTCH2, comparable to normal CD19þ controls.
NOTCH1 expression was signiﬁcant in 89% of patients, while
NOTCH3 was present in o40% of the samples. The signal for
NOTCH4 was typically below the threshold, as in our patient
sub-set (Figure 4b). Ligand expression was more variable, with
only 60–80% expressing JAG1, JAG2 and DLL1. This ﬁnding is
Table 1 Notch pathway gene expression in 207 high-risk pediatric pre-B ALL patients
Gene name Gene
symbol
Probeset ID Leukemic patients
(N¼207)
Normal controls
(CD19+ cells) (N¼6)
Median
Signal
% Present
Calls
Median
Signal
% Present
Calls
NOTCH receptors
Notch homolog 1 NOTCH1 218902_at 743 89 868 83
Notch homolog 2 NOTCH2 202443_x_at 917 97 4503 100
Notch homolog 3 NOTCH3 203238_s_at 234 38 104 17
Notch homolog 4 NOTCH4 205247_at 206 43 275 17
NOTCH ligands
Jagged 1 JAG1 216268_s_at 228 64 513 83
Jagged 2 JAG2 32137_at 347 81 278 33
Delta-like 1 DLL1 224215_s_at 479 58 443 17
Delta-like 3 DLL3 230568_x_at 212 34 273 0
Delta-like 4 DLL4 223525_at 107 11 132 0
Delta-like 1 homolog DLK1 209560_s_at 150 30 205 50
HES family downstream targets
Hairy and enhancer of split 1 HES1 203394_s_at 170 37 289 50
Hairy and enhancer of split 2 HES2 231928_at 159 20 135 0
Hairy and enhancer of split 4 HES4 227347_x_at 65 7 46 0
Hairy and enhancer of split 5 HES5 239230_at 69 9 132 0
Hairy and enhancer of split 6 HES6 226446_at 276 42 118 0
Hairy and enhancer of split 7 HES7 224548_at 128 14 246 0
Hairy/enhancer-of-split related with YRPW motif 1 HEY1 44783_s_at 483 98 797 100
Hairy/enhancer-of-split related with YRPW motif 2 HEY2 219743_at 240 48 262 17
Hairy/enhancer-of-split related with YRPW motif-like HEYL 226828_s_at 230 49 247 17
NOTCH processing
ADAM metallopeptidase domain 10 ADAM10 202604_x_at 646 96 492 83
ADAM metallopeptidase domain 17 ADAM17 205745_x_at 1150 99 660 100
MFNG O-fucosylpeptide 3-b-N-acetylglucosaminyl-transferase MFNG 204153_s_at 1460 98 1332 100
RFNG O-fucosylpeptide 3-b-N-acetylglucosaminyltransferase RFNG 212968_at 521 81 408 33
LFNG O-fucosylpeptide 3-b-N-acetylglucosaminyltransferase LFNG 228762_at 282 32 675 17
g-secretase components
Presenilin 1 PSEN1 203460_s_at 462 91 787 100
Presenilin 2 PSEN2 204262_s_at 108 17 285 0
Nicastrin NCSTN 208759_at 670 78 1117 83
Anterior pharynx defective 1 homolog A APH1A 1554417_s_at 186 40 79 0
Anterior pharynx defective 1 homolog B APH1B 221036_s_at 207 34 459 17
NOTCH regulation
Neuralized homolog NEURL 204889_s_at1 278 38 496 17
Neuralized homolog 2 NEURL2 230283_at 123 27 122 0
Mindbomb homolog 1 MIB1 224720_at 1033 100 1271 100
Mindbomb homolog 2 MIB2 226644_at 399 65 287 0
Deltex homolog 1 DTX1 227336_at 775 73 894 100
Deltex homolog 2 DTX2 215732_s_at 134 17 69 0
Deltex homolog 3 DTX3 222022_at 220 40 209 17
Deltex 3-like DTX3L 225415_at 1339 94 1590 100
Deltex homolog 4 DTX4 212611_at 761 87 1244 100
Numb homolog NUMB 209073_s_at 631 88 578 17
Nuclear proteins involved in NOTCH signaling
Mastermind-like 1 MAML1 202360_at 1752 99 1407 100
Mastermind-like 2 MAML2 235457_at 774 94 1355 100
Mastermind-like 3 MAML3 242794_at 633 89 452 83
Recombination signal-binding protein for Ig kappa J region (CSL) RBPJ 211974_x_at 5171 100 3665 100
Nuclear receptor co-repressor 1 NCOR1 200857_s_at 1356 100 1134 100
Nuclear receptor co-repressor 2 (SMRT) NCOR2 207760_s_at 1887 98 1938 100
Abbreviation: ALL, acute lymphoblastic leukemia.
Gray highlighting denotes genes for which at least one of probeset has median signal intensity 4225, set as threshold for ‘present call’.
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Leukemiaexpected in the high-risk group, at least for JAG1, whose
expression was previously correlated with good outcome.
25
Importantly, the majority of Notch pathway-related genes were
signiﬁcantly expressed in the high-risk ALL cohort.
Interesting exceptions were noted. For example, 91% of
patient samples and 100% of normal CD19þ controls had
signiﬁcant expression of the gene (PSEN1) encoding the
g-secretase component, presenilin 1. In contrast, expression of
the gene (PSEN2) encoding presenilin 2 was virtually absent
from patient samples and very low in normal CD19þ controls.
We observed strong correlation between expression of pairs of
genes in this analysis set (Supplementary Table 4). Thus,
genomic analyses reveal consistent expression of 430 addi-
tional Notch genes whose products are necessary for Notch
trafﬁcking and processing or that act to amplify or repress Notch
transcriptional events. Finally, by including data from two study
groups, we demonstrate that Notch gene expression is not linked
speciﬁcally to any of the genetic abnormalities that deﬁne
precursor-B ALL subsets. The 11 patient institutional group
included t(4;11) and t(1;19) translocations, as well as both
hyperdiploid and hypodiploid cases. The high-risk cohort used
for genomic analysis includes E2A/PBX (t(1;19)), BCR/ABL
(t(9;22)) and mixed lineage leukemia rearrangements, as well
as many others.
GSI-I shows therapeutic potential in a murine xenograft
model of human precursor-B ALL
Given our ﬁndings that GSI-I is effective in eliciting cell death in
precursor-B ALL cell lines and primary patients samples, it is
reasonable to ask if the compound might be an effective
therapeutic agent. We explored this possibility using NOD/SCID
mice engrafted with human pre-B ALL blasts. On day 1 of the
study, 23 mice were injected subcutaneously with 5 10
6
viable 697 cells; an additional mouse was used as a negative
histology control. To avoid potential drug–drug interactions,
GSI-I was used as a single agent in the experimental group
(n¼12). After a 1-month incubation period, GSI treatment was
initiated in the experimental group with dosing schedule
consisting of 5 days on, 2 days off and 5 days on. The 11 mice
in the engrafted control group were given normal saline
injections under the same schedule. Within 50–64 days, two
mice in the control group and one mouse in the treated group
were killed because of signs of progressive disease, as evidenced
by weight loss, loss of appetite and decreased movement. At
necropsy, affected mice showed signiﬁcant disease burden in
the liver and bone marrow (Figures 5a–c). We performed post-
euthanasia necropsies on all remaining mice in both groups at
day 72 and found that all eight surviving mice in the control
group had profound histologic evidence of disease.
Notably, only half of the 12 GSI-I-treated group showed signs
of disease (Table 2). The effect on GSI-I on disease progression
in the NOD/SCID xenograft model of precursor-B ALL was
statistically signiﬁcant (P¼0.0091, log-rank test). This is a
remarkable ﬁnding, because it was used as a single agent for
only one course of therapy (Figure 5d).
Discussion
The therapeutic potential of g-secretase inhibitors in the human
acute leukemias has focused on T-ALL,
1 where up to 50% of
cases harbor activating Notch 1 mutations.
26 The involvement
of Notch in early B-cell malignancies was largely dismissed,
based on Notch1 association with the T-cell lineage commit-
ment and evidence that overexpression of ICNs or Hes1 induces
Figure 5 Detection of precursor-B ALL blasts in blood (a), bone marrow (b) and liver (c) after engraftment of nonobese diabetes/severe combined
immunodeﬁciency (NOD/SCID) mice with 697 cells. The image in (d) shows a liver free of blasts in a GSI-treated animal. (a), (c) and (d) are
hematoxylin and eosin (H&E)-stained sections; the bone marrow sample in (b) shows immunohistochemical staining for human CD10, to
distinguish blast cells from any potential leukocyte progenitors in this immunocompromised mouse.
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Leukemiaapoptosis in pre-B cell lines.
27 Nevertheless, there are previous
reports of JAG1 expression in precursor-B ALL cells
25 and Notch
receptors, ligands and targets have been implicated at various
stages of B-cell development.
28 Notch dysregulation has been
documented in mature B-cell neoplasms, including multiple
forms of lymphoma, B-cell chronic lymphoid leukemia and
multiple myeloma.
5,9,29,30,31 In mice, retroviral-mediated gene
disruption implicated Notch-related genes (Notch 2, presenilin
1, Dtx2, Numb and ADAM) in pro-B and pre-B leukemo-
genesis,
32 while long-term GSI treatment led to altered
maturation of peripheral B cells.
33 Here, we deﬁnitively show
that expression of both Notch ligands and receptors are
common features of leukemic B-cell precursors. This conclusion
is based on analysis of 11 institutional patients and 207 high-risk
patients enrolled in COG P9906. We further show that GSI-I
induces cell death in precursor-B ALL cells ex vivo and in vivo
using cell survival assays and a NOD/SCID xenograft model.
There are clear differences between Notch gene expression
patterns and mutational status in the two lymphoid forms of
acute leukemia, precursor-B ALL and T-ALL. First, comparison
of gene expression proﬁles reported of T-ALL cells treated with
GSIs
34 shows only a small percentage of overlap between the
gene sets in these studies, most notably the Notch target Myc.
Massive induction of HSP70 and other stress response genes was
not seen in T-ALL cells treated with DAPT or compound E,
11,34
despite previous connections between presenilin function and
the unfolded protein response.
35 The unexpected induction of
Hes1 by GSI treatment (Figure 4) was also reported by others for
B-cell leukemia and acute myeloid leukemia cell lines.
4 Hes1
expression is also linked to activation of the JNK stress response
pathway, which is elevated after GSI-I treatment (Figure 2b).
36
Another explanation may be cross-talk between the Notch and
NFkB pathways,
37 because IkBa can bind the Hes1 promoter
and suppress Hes1 gene expression.
38 Active Notch may
compete with IkBa to bind with NFkB, thereby enabling
increased Hes1 expression. By 6 h treatment with GSI, several
genes associated with the NFkB pathway have signiﬁcantly
altered expression levels in precursor-B ALL cells (Supplemen-
tary Tables 3A and B).
We found that transcription of most Notch target genes in
precursor-B ALL is modest compared with that reported for
T cells. As a result of low expression levels, conﬁrmation by
quantitative PCR methods is an important part of our study. We
suspect that Notch signaling at this stage of B-cell development
is held in check by inhibitory cis-interactions between receptors
and ligands expressed in the same cell, as recently demonstrated
in elegant studies by Sprinzak et al.
39 We note also that
g-secretase may have other signiﬁcant targets in precursor-B ALL
leukemia cells. CD44 (ref. 8) is one likely candidate that merits
further study.
Others have raised the possibility that GSIs might inhibit other
cellular proteases.
3 Our study conﬁrms that GSI-I also inhibits
the proteosome, an important cancer therapeutic target.
14,15,39
Importantly, both protease pathways are mechanistically linked
to apoptosis. Caspase activation and oxidative stress was found
to be synergistic in chronic lymphoid leukemia cells treated
with the proteasome inhibitor NPI-0052.
40 ROS production
distinguishes the killing activity of GSI-I from bortezomib
(Figure 3), consistent with disruption of Notch-mediated anti-
apoptotic pathways that protect mitochondrial function and
prevent induction of pro-apoptotic Bcl2 family members like
Bim
41 and Bax.
42
The signiﬁcant enhancement in ALL blast cell killing because
of GSI-I’s dual inhibitory properties follows the recent trend of
combined, targeted therapeutic regimens. In T-ALL, recent
studies in mice have suggested that the combination of
dexamethasone with compound E could enhance toxicity while
protecting against GSI-induced gut toxicity.
40 Other promising
studies in mice combined a 3-day on/4-day off GSI dosing
schedule with an mammalian target of rapamycin inhibitor.
43
Our animal studies also showed a signiﬁcant protective effect on
an intermittent schedule, supporting the concept that short-term
or periodic treatment with inhibitors (like GSI-I) that target
multiple proteases might sensitize precursor-B ALL leukemia
cells to chemotherapeutic reagents with less severe toxicity to
normal organs. With these ﬁndings, we wish to further explore
the effects of GSI-I in additional pre-clinical studies.
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Table 2 Summary of results in human precursor-B ALL xenograft
model
Mouse
number
% Blasts in
blood smear
% Blasts in bone
marrow aspirate
Liver
inﬁltration
hCD10 in
bone marrow
Untreated
1 0 8–11 + +++
2 0 3–6 ++ +
3 4–6 39–44   ++
4N D B100 +++ +++
5 0–1 2 + +
60 2   +
7 51–56 B100 +++ +++
8 41–43 B100 +++ +++
9 8–10 41–46 ++ +++
10 12–15 39–43 ++ ++
11 0 0–1 + +
GSI-I treated
1
a 00   
2 41–45 B100 +++ +++
3
a 00   
4 1–3 6–11 ++ +++
5
a 00   
6 3–6 ND ++ +
7 8–11 ND ++ ++
8 19–22 56–58 +++ +++
9
a 00   
10
a 00   
11 8–12 44–46 +++ +++
12
a 00   
Abbreviations: ALL, acute lymphoblastic leukemia; GSI, gamma
secretase inhibitor; ND, not done.
aIn all, 6 of 12 treated mice free of disease after GSI-I treatment.
+, few nodules (1–5).
++, multiple nodules (45).
+++, large areas inﬁltrated.
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